At Abbott, we prioritize a healthy cardiovascular system by advancing heart and vascular disease treatments through breakthrough, less-invasive medical technologies. Our Clonmel facility in Co Tipperary plays a crucial role in meeting global demand for vascular devices, enhancing treatment options for coronary artery disease, mitral regurgitation, and peripheral artery disease.
Established in 1998 and acquired by Abbott in 2006, our Clonmel site has grown significantly, including the addition of a Research & Development Centre in 2015. Our vision is to be a great place to work and lead in innovating, building, and delivering life-changing medical devices. We take pride in our products, ensuring they are built with the same care as if intended for our own families. The facility manufactures a wide range of vascular devices, including stent delivery systems and vessel closure products.